At a glance
ClinicalIndex Comparison RecordN/ACompleted· 25 enrolled
Drug / intervention
Resveratrol +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of 6 Weeks Resveratrol Supplementation on Vascular Function in CKD
In Brief
A clinical study evaluating Resveratrol and Placebo for Chronic Kidney Diseases and Endothelial Dysfunction. Completed, enrolled 25 participants across 1 site.
Detailed Summary
The proposed research is clinical study evaluating the therapeutic benefits of resveratrol on vascular function in patients with chronic kidney disease (CKD). The study aims to establish that resveratrol will improve endothelial function and functional performance by reducing oxidative stress and in conjunction with lowering markers of inflammation and oxidative stress.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Diseases, Endothelial Dysfunction
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedJul 2018
Enrollment StartJan 2019
Primary CompletionJan 2023
TodayJul 2026
First PostedJul 24, 2018
Enrollment StartJan 1, 2019
Primary CompletionJan 12, 2023
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 7.9 years ago
Interventions
Resveratroldietary
Oral supplementation for 6 weeks
Placeboother
Oral supplementation for 6 weeks